Search Results
Therapeutic targeting of T-cell acute lymphoblastic leukemia using an AKR1C3-activated prodrug
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive malignancy that is exceptionally difficult to cure after relapse. We have previously shown that T-ALL expresses high levels of the enzyme AKR1C3, leading to clinical trials of AKR1C3-activated prodrugs. This project will focus on identifying the determinants of responses to AKR1C3-activated prodrugs in T-ALL and optimizing the use of a second generation AKR1C3-activated prodrug, SN36008, in T-ALL patient-derived xenografts.
Forbes Women’s Summit 2019: LLS’s Chief Medical Officer Joins Women In Leading the Way
More than 400 women from diverse backgrounds in business, entertainment, fashion, media, healthcare, science and finance came together this week to inspire and encourage one another at the 2019 Forbes Women’s Summit at Pier 60 Chelsea Piers in New York City.
The attendees engaged in animated discussions about how women are changing the world while still fighting to overcome obstacles they face in the workforce and on the world stage.
Companies Take on Blood Cancer
Corporations usually have enough on their plate, just taking care of business, but at least one has found a creative way to also help generate millions of dollars to fund blood cancer research, education and patient services.
Researcher Q&A: Christopher Cogle, M.D., University of Florida
Christopher Cogle, M.D., Professor of Medicine, University of Florida, Pierre Chagnon Professor of Stem Cell Biology and Bone Marrow Transplant, is the recipient of an LLS Scholar in Clinical Research grant through our Career Development Program. He also has a project supported through LLS’s Therapy Acceleration Program. Dr. Cogle explains his work advancing an investigational approach to treating patients with acute myeloid leukemia and myelodysplastic syndromes.
Pluripotent Stem Cell-derived CAR-T and CAR-NK Cells for Immunotherapy of Leukemia and Lymphoma
Cytotoxic cells of the immune system, including T and NK cells, can be targeted to seek out and destroy leukemia, lymphoma and myeloma cells by engineering them to express chimeric antigen receptors (CARs) which empower the cell to home to and kill the cancer cells. Typically, such CAR-T and CAR-NK cells are generated from a patient's own blood, but sometimes heavy pre-treatment with chemotherapy leaves inadequate supplies of T and NK cells.Putting Patients at the Center of Care at #ASCO16
The American Society of Clinical Oncology (#ASCO16) annual meeting kicked off today as more than 30,000 researchers from around the world converged in Chicago to share their latest clinical findings on treatments and diagnostics for all cancers, and to exchange ideas about how to improve outcomes for cancer patients.
Can We Start Using The Word “Cure?” #ASH17
Today at the #ASH17 (American Society of Hematology) conference in Atlanta, researchers presented the latest compelling data from thousands of clinical trials, revealing how experimental therapies, or approved therapies being tested in new ways, have worked in treating blood cancer patients. Among the presentations were several hundred projects across a spectrum of diseases that benefited in some way from support from The Leukemia & Lymphoma Society (LLS).
“I Don’t Have Money but I Have Time”
Three or four days a week for the past five years, Dorothy Spriggs has been showing up for work at The Leukemia & Lymphoma Society’s (LLS) Maryland chapter. However, instead of a paycheck, she is earning the satisfaction of knowing she is doing her part to give back and helping others with blood cancer.
At age 73, the Baltimore woman known as “Ms. Dotti” has no plans to stop. She’s enjoying it way too much.
“It’s the joy of being able to give back in a small way,” she said. “When I look at what the staff do, it amazes me. What I do is kind of small compared to them.”
Progress and Challenges in Treating the Blood Cancers: #ASH19
It’s that time of year again, when more than 30,000 scientists specializing in blood cancers and other blood disorders, oncologists and hematologists, pharmaceutical and biotechnology company representatives, and cancer patient advocacy organizations gather in one place to learn about the latest progress in treatments and share new ideas.
This year, we’re in sunny Orlando for the 61st ASH (American Society of Hematology) Annual meeting and Exposition.
6-Thioguanine
6-Thioguanine is FDA approved for remission induction and remission consolidation treatment of acute nonlymphocytic leukemias.
Cleaning Tips to Help Keep You and Your Loved Ones Safe
The Leukemia & Lymphoma Society (LLS) is here to help. We’ve put together guidance from the U.S. Centers for Disease Control and Prevention (CDC) and other tips to help caregivers and families keep their homes clean and healthy.
Healing Happens Around The Dinner Table
Too many parents lose their children to blood cancer each year. It’s a devastating experience for families blindsided by the harsh realities of cancer treatment that wasn’t developed with their little ones in mind. These lives lost too soon are the reason parents of children touched by blood cancer advocate fervently for change. And it’s a cause their communities and loved ones are more than happy to join—developing better treatment options that are safer and more effective for children, causing fewer side effects and leading to better outcomes.
What I’ve Learned: Tips for Parents of Kids with ALL
My daughter Mackenzie was diagnosed with acute lymphoblastic leukemia (ALL) in January 2014. Despite being the most common form of childhood cancer that has a very prescribed protocol with better-than-most survival rates, the diagnosis petrified me. My nine-year-old had cancer.
CAR-T Pioneer Dr. Carl June Elected to the U.S. National Academy of Science
The Leukemia & Lymphoma Society (LLS) congratulates Carl June, MD, of the University of Pennsylvania, whose groundbreaking research ushered in a new era in cancer immunotherapy, for his election into the U.S. National Academy of Science (U.S. NAS). Dr. June earned this prestigious honor through recognition by his peers for his “distinguished and continuing achievements in original research.”
SAVE THE DATE AGAIN: GETTING MARRIED AFTER CANCER
My name’s Dustin. December 3, 2016 was the date that I was supposed to get married to KT. It was a Saturday. We had that date set for over a year, but there was no wedding—we canceled it the Tuesday before. KT informed most of our guests with an explanatory text: “So, I have some unfortunate news. We’re going to have to call off the wedding this weekend. Dust got cold feet…and leukemia.”
Deciphering the interplay between apoptotic and signaling pathways to target T-lineage acute lymphoblastic leukemia
T-ALL is an aggressive leukemia with limited treatment options. T-ALL cells resist to dying by suppressing their suicide pathways. BH3 mimetics reactivate the suicide mechanisms to induce cell death. We showed that these drugs are effective in T-ALL, but acquired resistance is due to the activation of growth-promoting signaling pathways. The proposed experiments will decipher the relationship between growth and death pathways, identifying unique combination therapies to improve disease outcomes.
Moms In Training: Keeping on Track
Staying on track while you train for a walk or run event can be challenging at times. This is especially true for busy moms who barely have enough time to work out, let alone track their fitness progress.
Shop Online and In-Store at Walgreens to Support LLS
The Leukemia & Lymphoma Society (LLS) and Walgreens are in your corner.
Since 2019, Walgreens has helped to raise more than $30 million for LLS and Susan G. Komen, all with a clear goal in mind: to advance research for tough-to-treat cancers and increase equitable access to care.